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Recent studies demonstrate hat primary (hereditary) abnormalities in the glucocorticoid receptor gene make 
6.6% of the normal population relatively "hypersensitive" to glucocorticoids, while 2.3% are relatively "re- 
sistant." These abnormalities might explain why some individuals develop severe adverse ffects during low dose 
glucocorticoid therapy, while others do not develop side effects even during long-term therapy with a much 
higher dose. Awareness of this heterogeneity n glucocorticoid sensitivity in the normal population might even- 
tually allow the prediction of a "safe" dose of glucocorticoid in individual patients. 
"Resistance" to the beneficial clinical effects of glucocorticoid therapy in part of the patients with severe 
rheumatoid arthritis and asthma is probably rarely related to generalized primary (hereditary) glucocorticoid 
resistance. In the majority of patients this "resistance" seems to be acquired and localized to the sites of 
inflammation, where it reflects high local cytokine production, which interferes with glucocorticoid action. 
Recognition of localized, acquired glucocorticoid resistance is of great importance indicating as alternative drug 
therapy with other immune-modulating drugs like cyclosporin and methotrexate. Chronic high dose glucocor- 
ticoid treatment insuch patients is ineffective in alleviating symptomatology, while generalized side effects occur, 
reflecting the patient's normal systemic sensitivity to these drugs. (Steroids 61:157-160, 1996) 
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Introduction 
Exogenous glucocorticoids play an essential role in the 
acute and chronic therapy of a number of immune diseases 
such as asthma nd rheumatoid arthritis and contribute con- 
siderably to the prevention of allograft rejection after organ 
transplantation.t Two seemingly different aspects of gluco- 
corticoid therapy, however, have reduced our enthusiasm to 
use these compounds. 2 First is the unpredictable occurrence 
of severe side effects during chronic therapy, 3'4 with many 
studies demonstrating that the duration of therapy, the high- 
est steroid dose administered, and the total cumulative dose 
used are important predictors of adverse vents. 5 Unfortu- 
nately, it is currently impossible to define for a given patient 
a "safe" glucocorticoid ose that does not cause side ef- 
fects. 4'5 Second, the efficacy of glucocorticoid therapy in 
chronic immune disease is unpredictable. There is clinical 
and laboratory evidence that patients can be divided into 
"steroid-sensitive" and "resistant" groups. These differ- 
ences have been documented in the treatment of asthma 6"7 
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and rheumatoid arthritis, 8'9 as well as in renal graft recipi- 
ents. ~°'tl In this study we review several recent investiga- 
tions of the role(s) of hereditary and/or acquired abnormali- 
ties in glucocorticoid receptor function in man. The results 
of these studies are discussed against he background of the 
two main clinical questions concerning glucocorticoid 
therapy in immune disease: 1) that of an individual "safe 
dose," which can be used without the occurrence of side 
effects, and 2) that of the mechanism of the apparent "re- 
sistance" in part of the patient population treated with these 
drugs. 
Hereditary glucocorticoid resistance 
Primary hereditary glucocorticoid resistance is a rare disor- 
der, which has only been described in a dozen individuals to 
date. z2-15 In this syndrome the abnormal receptor alters 
feedback inhibition of the hypothalamo-pituitary-adrenal 
axis, which is thus set at a higher level with slightly elevated 
plasma ACTH levels and increased circulating cortisol con- 
centrations. The diurnal rhythms of ACTH and cortisol se- 
cretion remain intact, while the system remains ensitive to 
external stresses uch as that caused by acute hypoglycemia. 
The elevated circulating cortisol evels do not cause signs or 




bers of impaired glucocorticoid receptors are present in all 
target issues. Symptoms of glucocorticoid resistance stem 
primarily from ACTH-induced adrenocortical overstimula- 
tion, resulting in increased serum concentrations of andro- 
gens and mineralocorticoids. The wide variation in the 
nature and severity of the symptoms associated with gluco- 
corticoid resistance can made its diagnosis difficult. ~6'~7 
Hypercortisolism and/or an inadequate r sponse to a 1 mg 
overnight dexamethasone suppression test can point to this 
abnormality. ~6'~7 Hormone profiles (androgens, mineralo- 
corticoids) and analysis of the number and affinity of glu- 
cocorticoid receptors in peripheral blood mononuclear leu- 
cocytes or in cultured skin fibroblasts are usually carried 
out. Bioassays to measure glucocorticoid sensitivity can 
also be performed on lymphocytes or fibroblasts. 
The molecular mechanisms of glucocorticoid resistance 
detected to date reflect at least three different abnormalities. 
First, missense mutations in the ligand binding domain of 
the glucocorticoid receptor gene causing decreased ligand 
binding affinity have been reported in two different fami- 
18 19 lies. • Second, a deletion of four base pairs at the bound- 
ary of exon 6 of the glucocorticoid receptor and the follow- 
ing intron has been demonstrated to be responsible for the 
loss of a splice site and the production of an unstable 
mRNA. This deletion allows only one allele to be ex- 
pressed, resulting in a decrease of glucocorticoid receptor 
protein by 50% in affected members of this glucocorticoid- 
resistant family. 2° Third, a novel glucocorticoid receptor 
gene mutation has recently been discovered in the ligand 
binding domain of the glucocorticoid receptor, in which a 
point mutation in exon 5 is accompanied by a significant 
loss of function of the receptor protein, as indicated by 
transfection studies. Interestingly, in cotransfection studies 
this mutant receptor exerted a dominant negative ffect on 
the wild type glucocorticoid receptor, causing the lowered 
glucocorticoid receptor affinity observed in this heterozy- 
gous patient's peripheral lymphocytes. 21 In addition to these 
three distinct molecular mechanisms of glucocorticoid re- 
sistance, cases have been reported where increased thermo- 
lability of the glucocorticoid receptor or a reduced capacity 
to bind DNA were the cause of glucocorticoid resis- 
tance. 15'22 In these cases, however, abnormalities in the glu- 
cocorticoid receptor gene have not yet been reported. 
Glucocorticoid receptor abnormalities in the 
normal population 
The recent reports of a significant prevalence of possible 
abnormalities in the glucocorticoid receptor in patients at- 
tending the endocrine clinic for hypokalemia, hypertension, 
acne, hirsutism, and menstrual disorders prompted us to 
carry out a cross-sectional study on the prevalence of glu- 
cocorticoid receptor abnormalities in a group of 216 healthy 
elderly individuals (J.W. Koper et al., unpublished obser- 
vations). In the 1 mg overnight dexamethasone suppression 
test 17 persons showed "diminished" suppression, with 
postdexamethasone cortisol evels above 50 nmol/L. In 16 
of these "diminished" suppressors and in 10 age- and sex- 
matched subjects with a normal suppression we analyzed 
glucocorticoid receptor number and affinity in mononuclear 
leukocytes and the biological response of these cells to glu- 
cocorticoids in a mitogen-stimulated lymphocyte prolifera- 
tion assay. Of the "diminished" suppressors 10 were found 
to have abnormal results in the glucocorticoid receptor as- 
says versus none in the control group. Using polymerase 
chain reaction-based analysis of single strand conformation 
polymorphism, we screened for mutations in the glucocor- 
ticoid receptor gene. Five mutations in the glucocorticoid 
receptor gene were identified, all occurring in more than one 
person. Two of these mutations were significantly associ- 
ated with reduced glucocorticoid receptor function and were 
calculated to occur in 2.3% of the normal population. An- 
other single point mutation, present in 6.6% of these healthy 
elderly individuals, was associated with a significantly in- 
creased receptor function. These polymorphisms were not 
associated with clinical abnormalities but may contribute to 
the variable sensitivity to glucocorticoid therapy observed 
in the normal population. 
Transient and/or acquired 
glucocorticoid resistance 
The best known examples of acquired glucocorticoid resis- 
tance are the abnormalities in glucocorticoid receptor activ- 
ity in the neoplastic ells of most human hematologic ma- 
lignancies. Glucocorticoid receptor abnormalities, aswell as 
an increasing number of well characterized postreceptor ab- 
normalities, 23-25 play an important role in the ultimate prog- 
nosis of patients with acute leukemia nd malignant lym- 
phomas, z6 In the differential diagnosis of Cushing's syn- 
drome the degree of glucocorticoid resistance also plays an 
important role. Most tumors ectopically secreting ACTH 
are characterized by a high degree of glucocorticoid resis- 
tance, which has been demonstrated to be accompanied by 
changes in ligand binding in several human small cell lung 
cancer cell lines. 27 In Nelson's syndrome the cells of the 
expanding, infiltrating, ACTH secreting pituitary tumor 
have similarly been demonstrated to have a defect in the 
glucocorticoid receptor gene. 2s 
Acquired (localized) glucocorticoid resistance in rheu- 
matoid arthritis and asthma is accompanied by a reduction 
in the number of glucocorticoid receptors in circulating leu- 
kocytes 29 and/or a reversible decrease in the affinity of glu- 
cocorticoid receptors in T lymphocytes, 3° respectively. 
Similarly, in some patients with AIDS, peripheral leuko- 
cytes demonstrate a marked decrease in the affinity of glu- 
cocorticoid receptors for cortisol. 31 Glucocorticoids are 
known to be powerful suppressors of the activity of the 
immune system. Inhibition of chemotaxis and bactericidal 
activity in neutrophils and monocytes, lymphopenia, de- 
creased macrophage function, and disturbed complement 
activation are well known effects of glucocorticoid admin- 
istration.~ Most of the effects of glucocorticoids on the im- 
mune system are thought o be mediated via inhibition of 
transcription of various cytokine genes, particularly those 
coding for interleukin-1 (IL-1) and IL-6 in macrocytes/ 
macrophages, 3e and IL-2 in lymphocytes. 33'34 However, 
higher concentrations of cytokines, especially IL-2, antago- 
nize the suppressive ffects of glucocorticoids in a dose- 
dependent manner, thus counteracting these transcriptional 
effects. 35 The balance between glucocorticoid action and 
the production of interleukins in mitogen-stimulated im- 
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mune cells is in most cases in favor of glucocorticoids, 
which override the activity of the immune cells. A number 
of studies uggest that at the site of inflammation i cases of 
rheumatoid arthritis, asthma, and sepsis, high local concen- 
trations of cytokines in fact induce a localized glucocorti- 
coid resistance, which cannot be overcome by excess exog- 
enous glucocorticoids. 3°'35"36"37 
Conclusions 
Recent evidence suggests that primary (hereditary) abnor- 
malities in the glucocorticoid receptor gene cause relative 
"hypersensitivity" to glucocorticoids in 6.6% of the normal 
population, while 2.3% is relatively "resistant." These dif- 
ferences in -10% of the normal population may thus con- 
tribute to the well known phenomenon of some individuals 
developing severe adverse ffects on low dose glucocorti- 
coid therapy, while others do not develop side effects during 
long-term therapy with much higher doses. Further studies 
on the heterogeneity of glucocorticoid sensitivity in the nor- 
mal population might thus eventually allow the prediction 
of a "safe" glucocorticoid dose in individual patients. 
"Resistance" to the beneficial effects of glucocorticoid 
therapy in patients with rheumatoid arthritis and asthma is 
related to generalized primary (hereditary) glucocorticoid 
resistance in only a small minority of these patients; in this 
group a higher dose of glucocorticoids might overcome the 
genetically determined resistance. However, in the majority 
of patients "resistance" seems to be acquired and localized 
at the inflammation site(s), where it is a consequence of
high cytokine production interfering with glucocorticoid ac- 
tivity. Recognition of localized, acquired glucocorticoid re- 
sistance is of great importance, as alternative drug therapy 
with other immune-modulating compounds uch as cyclo- 
sporin, methotrexate, and/or gold should be considered 
early on in the disease. In these circumstances chronic high 
dose glucocorticoids will insufficiently alleviate the symp- 
tomatology of the immune disease and cause general side 
effects, as the patient has a normal systemic sensitivity to 
the treatment. 
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